Literature DB >> 22976554

Neuromyelitis optica: potential roles for intravenous immunoglobulin.

Dean M Wingerchuk1.   

Abstract

Neuromyelitis optica (NMO) is an idiopathic central nervous system inflammatory demyelinating disease that causes optic neuritis, transverse myelitis, and other CNS syndromes. It is distinct from multiple sclerosis and is associated with autoantibodies that target aquaporin-4 (AQP4), an astrocyte water channel. Evidence indicating antibody-mediated immune injury in NMO includes its association with other autoimmune diseases, lesional pathology that reveals prominent complement activation and immunoglobulin deposition, pathogenic potential of AQP4 autoantibodies based on in vitro studies, and reports of putative animal models of the disease. The rationale and potential role for intravenous immunoglobulin in NMO will be discussed in the context of both relapse treatment and relapse prevention.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22976554     DOI: 10.1007/s10875-012-9796-7

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  31 in total

1.  Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.

Authors:  C Costanzi; M Matiello; C F Lucchinetti; B G Weinshenker; S J Pittock; J Mandrekar; P Thapa; A McKeon
Journal:  Neurology       Date:  2011-08-03       Impact factor: 9.910

2.  A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

Authors:  B G Weinshenker; P C O'Brien; T M Petterson; J H Noseworthy; C F Lucchinetti; D W Dodick; A A Pineda; L N Stevens; M Rodriguez
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

Review 3.  Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  H S Patwa; V Chaudhry; H Katzberg; A D Rae-Grant; Y T So
Journal:  Neurology       Date:  2012-03-27       Impact factor: 9.910

4.  Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.

Authors:  M I Leite; E Coutinho; M Lana-Peixoto; S Apostolos; P Waters; D Sato; L Melamud; M Marta; A Graham; J Spillane; A M Villa; D Callegaro; E Santos; A Martins da Silva; S Jarius; R Howard; I Nakashima; G Giovannoni; C Buckley; D Hilton-Jones; A Vincent; J Palace
Journal:  Neurology       Date:  2012-05-02       Impact factor: 9.910

5.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

6.  Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders.

Authors:  S M Magaña; M Matiello; S J Pittock; A McKeon; V A Lennon; A A Rabinstein; E Shuster; O H Kantarci; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2009-02-24       Impact factor: 9.910

Review 7.  The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.

Authors:  Marinos C Dalakas
Journal:  Pharmacol Ther       Date:  2004-06       Impact factor: 12.310

8.  Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG).

Authors:  Jacqueline Bakker; Luanne Metz
Journal:  Can J Neurol Sci       Date:  2004-05       Impact factor: 2.104

9.  Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

Authors:  Anu Jacob; Brian G Weinshenker; Ivo Violich; Nancy McLinskey; Lauren Krupp; Robert J Fox; Dean M Wingerchuk; Mike Boggild; Cris S Constantinescu; Aaron Miller; Tracy De Angelis; Marcelo Matiello; Bruce A C Cree
Journal:  Arch Neurol       Date:  2008-09-08

10.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

View more
  15 in total

1.  Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder.

Authors:  Youming long; Yihua He; Yangbo Zheng; Mengyu Chen; Bin Zhang; Cong Gao
Journal:  J Neurol       Date:  2013-12       Impact factor: 4.849

2.  Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica.

Authors:  Sho Nobuyoshi; Akiyasu Kanamori; Yoshiko Matsumoto; Makoto Nakamura
Journal:  Jpn J Ophthalmol       Date:  2016-06-07       Impact factor: 2.447

Review 3.  Emerging therapeutic targets for neuromyelitis optica spectrum disorder.

Authors:  Lukmanee Tradtrantip; Nithi Asavapanumas; Alan S Verkman
Journal:  Expert Opin Ther Targets       Date:  2020-03-02       Impact factor: 6.902

4.  Effects of pooled human immunoglobulins in an animal model of neuromyelitis optica with chronic application of autoantibodies to aquaporin 4.

Authors:  C Geis
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

5.  Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica.

Authors:  Julien Ratelade; Alex J Smith; A S Verkman
Journal:  Exp Neurol       Date:  2014-03-14       Impact factor: 5.330

6.  Intravenous immunoglobulin as the rescue treatment in NMOSD patients.

Authors:  Jie Lin; Binbin Xue; Ruofan Zhu; Juyuan Pan; Jia Li; Yan Lin; Xiang Li; Junhui Xia
Journal:  Neurol Sci       Date:  2021-02-01       Impact factor: 3.307

7.  Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica.

Authors:  Richard K Burt; Roumen Balabanov; Xiaoqiang Han; Carol Burns; Joseph Gastala; Borko Jovanovic; Irene Helenowski; Jiraporn Jitprapaikulsan; James P Fryer; Sean J Pittock
Journal:  Neurology       Date:  2019-10-02       Impact factor: 9.910

Review 8.  The treatment of neuromyelitis optica.

Authors:  Markus C Kowarik; John Soltys; Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2014-03       Impact factor: 3.042

9.  C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica.

Authors:  Puay-Wah Phuan; Hua Zhang; Nithi Asavapanumas; Michael Leviten; Arnon Rosenthal; Lukmanee Tradtrantip; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-05-16       Impact factor: 15.887

10.  Severe aquaporin 4-IgG-positive neuromyelitis optica with disseminated herpes zoster in a pregnant woman successfully treated with intravenous immunoglobulin.

Authors:  Yuki Matsumoto; Mario Tsuchiya; Shakespear Norshalena; Chikako Kaneko; Jin Kubo; Teiji Yamamoto; Toshiyuki Takahashi; Kazuo Fujihara
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.